藤井 康智YASUTOSHI FUJII

Last Updated :2024/07/03

所属・職名
病院（医）　助教
メールアドレス
fujiiyasuhiroshima-u.ac.jp

研究活動

学術論文（★は代表的な論文）

  1. Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study, Jpn J Clin Oncol, 20240207
  2. Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma, Cancer Med, 202405
  3. Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs, Hepatol Res, 20240527
  4. Clinical Outcomes of Switching from Zoledronic Acid to Denosumab for the Management of Severe Bone Metastasis from Hepatocellular Carcinoma: A Single-Center, Open-Label, Prospective Intervention Trial, Yonago Acta Med, 20231107
  5. Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma-Consideration of the Locations of Target Lesions, Cancers, 20230130
  6. Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure, Hepatol Int, 202310
  7. Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein, Cancers, 20230414
  8. Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes, Eur J Gastroenterol Hepatol, 20230901
  9. Correlation between serum pro-inflammatory cytokine levels and the prognosis of the patients with acute liver failure, J Gastroenterol Hepatol, 202309
  10. Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment, Cancers, 20230824
  11. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma, Commun Med, 20231025
  12. Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma, Cancers, 20231114
  13. Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 36巻, 4号, pp. 430-437, 202404
    DOIを用いた論文検索結果へのリンク
  14. ★, Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma, CANCERS, 16巻, 7号, 202404
    DOIを用いた論文検索結果へのリンク

招待講演、口頭・ポスター発表等

  1. 当院における切除不能胆道癌に対するゲムシタビン＋シスプラチン＋デュルバルマブ併用療法の有効性と安全性に関する検討, 第60回日本肝臓学会総会, 2024年06月13日, 通常, 日本語
  2. 肝細胞癌の包括的がんゲノムプロファイリング検査の現状, 第110回日本消化器病学会総会, 2024年05月09日, 通常, 日本語
  3. 肝内胆管癌における包括的がんゲノムプロファイリング検査の現状と課題, 第59回日本肝癌研究会, 2023年07月27日, 通常, 日本語
  4. 切除不能肝細胞癌に対するデュルバルマブ＋トレメリムマブ併用療法の有効性と安全性に関する検討, 第29回日本肝がん分子標的治療研究会, 2024年01月26日, 通常, 日本語
  5. Peripheral T cell subpopulations during atezolizumab plus bevacizumab treatment for hepatocellular carcinoma, 第21回日本臨床腫瘍学会学術集会, 2024年02月22日, 通常, 英語